Research Status of Non-Epithelial Gastrointestinal Cancers in Vietnam
According to the BRAF mutation test (50%), the first regimen uses Vemurafenib, when there is no longer response, the second regimen is used with Ipilimumab. In addition, recent research shows that 15.6% have KIT mutations in skin lesions. In these cases, Imatinib is the treatment of choice for ...